What is the difference between isolate, broad-spectrum, and full-spectrum CBD?

Isolate is pure CBD with no THC; broad-spectrum includes multiple cannabinoids without THC; full-spectrum includes the full plant profile with up to 0.3% THC.

Is your CBD THC-free?

Our isolate and broad-spectrum products are THC-free. Product pages and labels list exact cannabinoid content.

How do I take CBD oil?

Most people place the oil under the tongue for 60-90 seconds before swallowing; start low and adjust gradually.

Hemp-derived CBD is federally legal under the 2018 Farm Bill; check your local regulations.

How do I place an order?

Choose a product above and tap Order, or email info@biomedrxmedicalmarijuana.com and we'll confirm your order by email.

BiomedRx Medical Marijuana | California Patient Education & Resources

Medical cannabis access and education.

Based in Upland, California, BiomedRx Medical Marijuana provides Health & Safety Code-compliant 215 recommendations, CBD and cannabis patient education, strain consultation, and dedicated programs for seniors and veterans. We do not sell, possess, or distribute cannabis — we guide compliant access.

Educational

Federal Rescheduling in 2026: What the April Schedule III Order Does — and Doesn't — Do

On April 23, 2026, the U.S. Department of Justice issued a final order reclassifying two specific categories to Schedule III of the Controlled Substances Act: marijuana contained in an FDA-approved drug product, and marijuana subject to a qualifying state medical-marijuana license. This is a notable but narrow change. All other cannabis — including adult-use (recreational) cannabis not covered by those categories — remains in Schedule I. This page is educational only and does not facilitate the sale, possession, or distribution of cannabis.

For patients, it is important to understand what rescheduling is not. It does not make state-authorized cannabis products FDA-approved medicines, it does not create a federal prescribing pathway at the pharmacy counter, and it does not erase the differences between federal and California law. A separate DEA administrative hearing was scheduled in mid-2026 to consider broader rescheduling questions, and the timing and outcome of any further action can change.

Cannabis is not FDA-approved to diagnose, treat, cure, or prevent any disease. Anyone considering medical cannabis should consult a licensed healthcare provider about their condition, medications, and possible interactions, and should verify current rules with official sources.

Sources: Federal Register — Rescheduling of FDA-approved marijuana products (Apr 2026); DEA — Marijuana Rescheduling Regulatory Actions

Jul 8, 202615 min read

Informative

California DCC Rulemaking in 2026: Track-and-Trace, A/M Licensing, and What It Means for Patients

California's Department of Cannabis Control (DCC) has been active in 2026. Proposed track-and-trace updates would require all parties to a transfer to approve it before a shipping manifest is generated, add data-entry clarifications, and require retailers to provide Certificates of Analysis (COAs) to customers on request — a transparency point patients can use to ask about lab testing. Public comment on those changes ran through July 2026. Separately, the DCC moved to let licensees holding both medicinal and adult-use designations obtain separate medicinal and adult-use licenses, in response to federal rescheduling.

For patients, the practical takeaway is about informed, compliant access: you can ask a licensed retailer for a product's COA, and medicinal-designated products remain governed by California's medical framework. Rules continue to evolve, so verify current requirements with official state sources rather than summaries.

This is general educational information, not legal or medical advice, and it does not facilitate the sale, possession, or distribution of cannabis. Cannabis is not FDA-approved to diagnose, treat, cure, or prevent any disease; consult a licensed provider about your situation.

Sources: DCC — Track and Trace Updates (2026); California Department of Cannabis Control

Jul 2, 202610 min read

Field Notes

Field Notes: "Does Rescheduling Mean I Can Get It at CVS Now?" — The Question We Heard All Summer

After the April 2026 rescheduling news, the single most common question from patients this summer was some version of "does this mean I can just pick it up at the pharmacy?" The short answer is no. The Schedule III order applies to FDA-approved drug products and state-licensed medical cannabis — it did not turn dispensary products into pharmacy prescriptions, and it did not change how day-to-day access works for most California patients, which still runs through the state's medical framework.

These conversations are educational, not transactional: we explain the process and point people to official sources, and we do not sell, possess, or distribute cannabis. The evidence base itself remains mixed — NIH and National Academies reviews note some support for cannabis in certain chronic-pain contexts while much else is limited or preliminary — so "start low, go slow" under professional guidance remains the sensible posture, especially for older adults on multiple medications.

We make no medical promises. Cannabis is not FDA-approved to diagnose, treat, cure, or prevent any disease. Consult a licensed physician or pharmacist about interactions and safety before considering it.

Sources: NIH NCCIH — Cannabis and Cannabinoids; U.S. DOJ — Schedule III placement (Apr 2026)

Jun 27, 20266 min read

Explore your options.

Tell us about your condition or concerns. We'll explain how medical cannabis may fit into your health plan and what the process looks like.

All services comply with California Health and Safety Code §11362.5 and §11362.7. BiomedRx does not sell, possess, or distribute cannabis. We provide compliant access guidance and patient education only.